Effects of nebivolol in obese African Americans with hypertension (NOAAH): Markers of inflammation and obesity in response to exercise-induced stress

Journal of Human Hypertension

Volumn 25, Issue 3, 2011, Pages 196-202

  Merchant, N ^a   Rahman, S T ^b   Ferdinand, K C ^a   Haque, T ^a   Umpierrez, G E ^a   Khan, B V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

Author keywords

exercise induced stress; inflammation; obesity

Indexed keywords

ADIPONECTIN; INTERLEUKIN 6; LEPTIN; NEBIVOLOL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; MALE; OBESITY; PHYSICALLY INDUCED STRESS; PROTEIN BLOOD LEVEL; TREADMILL EXERCISE;

ADIPONECTIN; AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ETHANOLAMINES; EXERCISE; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; INTERLEUKIN-6; LEPTIN; LIPIDS; MALE; MIDDLE AGED; OBESITY; STRESS, PHYSIOLOGICAL; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79951680124     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.39     Document Type: Article

References (30)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K et al. Heart disease and stroke statistics- 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115(5): e69-171.
2. Cooper R, Rotimi C. Hypertension in blacks. Am J Hypertens 1997; 10(7 Part 1): 804-812. (Pubitemid 27313828)
3. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49(1): 69-75. (Pubitemid 46360343)
4. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part 1: estimates of blood pressure levels. J Hypertens 2006; 24(3): 413-422. (Pubitemid 43261900)
5. Tong W, Lai H, Yang C, Ren S, Dai S, Lai S. Age, gender and metabolic syndrome-related coronary heart disease in US adults. Int J Cardiol 2005; 104(3): 288-291. (Pubitemid 41375588)
6. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumposalo E, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288(21): 2709-2716. (Pubitemid 35403784)
7. Grundy SM. Inflammation, hypertension, and the metabolic syndrome. JAMA 2003; 290(22): 3000-3002.
8. Hattori Y, Akimoto K, Gross SS, Hattori S, Kasai K. Angiotensin-II- induced oxidative stress elicits hypo-adiponectinaemia in rats. Diabetologia 2005; 48(6): 1066-1074. (Pubitemid 40909640)
9. Kim S, Whelan J, Claycombe K, Reath DB, Moustaid-Moussa N. Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandin-independent mechanism. J Nutr 2002; 132(6): 1135-1140. (Pubitemid 34606440)
10. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26(8): 2442-2450.
11. Cote M, Mauriege P, Bergeron J. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005; 90(3): 1434-1439. (Pubitemid 40464000)
12. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54(2): 534-539.
13. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102(11): 1296-1301.
14. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372(6505): 425-432. (Pubitemid 24365442)
15. Hube F, Lietz U, Igel M. Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Horm Metab Res 1996; 28(12): 690-693. (Pubitemid 27057917)
16. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003; 92(3): 344-348. (Pubitemid 36897730)
17. Ritter JM. Nebivolol: endothelium-mediated vasodilat-ing effect. J Cardiovasc Pharmacol 2001; 38(Suppl 3): S13-S16.
18. Van de Water A, Janssens W, Van Neuten J. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adre-nergic antagonist. J Cardiovasc Pharmacol 1988; 11(5): 552-563.
19. Schafer K, Halle M, Goeschen C, Dellas C, Pynn M, Loskutoff DJ et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 2004; 24(1): 112-117. (Pubitemid 38082420)
20. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52(5): 818-827.
21. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290(2): 199-206. (Pubitemid 37430058)
22. Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002; 282(1): G1-G5.
23. Cockcroft JR, Chowienczyk PJ, Brett SE. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274(3): 1067-1071.
24. Van Bortel LM, Breed JG, Joosten J, Kragten JA, Lustermans FA, Mooij JM. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993; 21(6): 856-862. (Pubitemid 23160671)
25. Taddei S, Virdis A, Ghiadoni L, Salvetti A. The role of endothelium in human hypertension. Curr Opin Nephrol Hypertens 1998; 7(2): 203-209. (Pubitemid 28116662)
26. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104(5): 511-514. (Pubitemid 32738117)
27. Greenlund KJ, Daviglus ML, Croft JB. Differences in healthy lifestyle characteristics between adults with prehypertension and normal blood pressure. J Hyper-tens 2009; 27(5): 955-962.
28. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipide-mia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008; 207(6): 928-934.
29. Hildreth C, Saunders E. Hypertension in blacks: clinical overview. Cardiovasc Clin 1991; 21(3): 85-96.
30. Martin MY, Person SD, Kratt P, Prayor-Patterson HK, Kim Y, Salas M et al. Relationship of health behavior theories with self-efficacy among insufficiently active hypertensive African-American women. Patient Educ Couns 2008; 72(1): 137-145.